Literature DB >> 20019182

Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts.

Karen Fernandez1, Yelda Serinagaoglu, Sue Hammond, Laura T Martin, Paul T Martin.   

Abstract

Altered expression of proteins in the dystrophin-associated glycoprotein complex results in muscular dystrophy and has more recently been implicated in a number of forms of cancer. Here we show that loss of either of two members of this complex, dystrophin in mdx mice or alpha sarcoglycan in Sgca(-/-) mice, results in the spontaneous development of muscle-derived embryonal rhabdomyosarcoma (RMS) after 1 year of age. Many mdx and Sgca(-/-) tumors showed increased expression of insulin-like growth factor 2, retinoblastoma protein, and phosphorylated Akt and decreased expression of phosphatase and tensin homolog gene, much as is found in a human RMS. Further, all mdx and Sgca(-/-) RMS analyzed had increased expression of p53 and murine double minute (mdm)2 protein and contained missense p53 mutations previously identified in human cancers. The mdx RMS also contained missense mutations in Mdm2 or alternatively spliced Mdm2 transcripts that lacked an exon encoding a portion of the p53-binding domain. No Pax3:Fkhr or Pax7:Fkhr translocation mRNA products were evident in any tumor. Expression of natively glycosylated alpha dystroglycan and alpha sarcoglycan was reduced in mdx RMS, whereas dystrophin expression was absent in almost all human RMS, both for embryonal and alveolar RMS subtypes. These studies show that absence of members of the dystrophin-associated glycoprotein complex constitutes a permissive environment for spontaneous development of embryonal RMS associated with mutation of p53 and mutation or altered splicing of Mdm2.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20019182      PMCID: PMC2797901          DOI: 10.2353/ajpath.2010.090405

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  103 in total

1.  Pax7 is required for the specification of myogenic satellite cells.

Authors:  P Seale; L A Sabourin; A Girgis-Gabardo; A Mansouri; P Gruss; M A Rudnicki
Journal:  Cell       Date:  2000-09-15       Impact factor: 41.582

Review 2.  Pathologic classification of rhabdomyosarcomas and correlations with molecular studies.

Authors:  D M Parham
Journal:  Mod Pathol       Date:  2001-05       Impact factor: 7.842

3.  Reduced expression of dystroglycan in breast and prostate cancer.

Authors:  M D Henry; M B Cohen; K P Campbell
Journal:  Hum Pathol       Date:  2001-08       Impact factor: 3.466

4.  Anomalous dystroglycan in carcinoma cell lines.

Authors:  C Losasso; F Di Tommaso; A Sgambato; R Ardito; A Cittadini; B Giardina; T C Petrucci; A Brancaccio
Journal:  FEBS Lett       Date:  2000-11-10       Impact factor: 4.124

Review 5.  Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma.

Authors:  F G Barr
Journal:  Oncogene       Date:  2001-09-10       Impact factor: 9.867

6.  Loss of suppressor-of-fused function promotes tumorigenesis.

Authors:  Y Lee; R Kawagoe; K Sasai; Y Li; H R Russell; T Curran; P J McKinnon
Journal:  Oncogene       Date:  2007-04-23       Impact factor: 9.867

7.  Genetic modeling of Ras-induced human rhabdomyosarcoma.

Authors:  Corinne M Linardic; Christopher M Counter
Journal:  Methods Enzymol       Date:  2008       Impact factor: 1.600

8.  Altered expression of natively glycosylated alpha dystroglycan in pediatric solid tumors.

Authors:  Laura T Martin; Matthew Glass; Eniolami Dosunmu; Paul T Martin
Journal:  Hum Pathol       Date:  2007-07-19       Impact factor: 3.466

9.  Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells.

Authors:  Chun-Liang Chen; Abbey Loy; Ling Cen; Christina Chan; Fu-Chuan Hsieh; Gong Cheng; Bryant Wu; Stephen J Qualman; Keita Kunisada; Keiko Yamauchi-Takihara; Jiayuh Lin
Journal:  BMC Cancer       Date:  2007-06-28       Impact factor: 4.430

10.  PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound.

Authors:  L Cen; F-C Hsieh; H-J Lin; C-S Chen; S J Qualman; J Lin
Journal:  Br J Cancer       Date:  2007-09-17       Impact factor: 7.640

View more
  30 in total

Review 1.  Advances in pediatric rhabdomyosarcoma characterization and disease model development.

Authors:  D O'Brien; A G Jacob; S J Qualman; D S Chandler
Journal:  Histol Histopathol       Date:  2012-01       Impact factor: 2.303

2.  Low expression of ANT1 confers oncogenic properties to rhabdomyosarcoma tumor cells by modulating metabolism and death pathways.

Authors:  J Vial; P Huchedé; S Fagault; F Basset; M Rossi; J Geoffray; H Soldati; J Bisaccia; M H Elsensohn; M Creveaux; D Neves; J Y Blay; F Fauvelle; F Bouquet; N Streichenberger; N Corradini; C Bergeron; D Maucort-Boulch; P Castets; M Carré; K Weber; M Castets
Journal:  Cell Death Discov       Date:  2020-07-24

3.  Protected cytoskeletal-related proteins: Towards a resolution of contradictions regarding the role of the cytoskeleton in cancer.

Authors:  Daniel T Segarra; John M Yavorski; George Blanck
Journal:  Biomed Rep       Date:  2017-07-06

4.  Cavin-1 and Caveolin-1 are both required to support cell proliferation, migration and anchorage-independent cell growth in rhabdomyosarcoma.

Authors:  Fiorella Faggi; Nicola Chiarelli; Marina Colombi; Stefania Mitola; Roberto Ronca; Luca Madaro; Marina Bouche; Pietro L Poliani; Marika Vezzoli; Francesca Longhena; Eugenio Monti; Barbara Salani; Davide Maggi; Charles Keller; Alessandro Fanzani
Journal:  Lab Invest       Date:  2015-03-30       Impact factor: 5.662

5.  Deletion of Galgt2 (B4Galnt2) reduces muscle growth in response to acute injury and increases muscle inflammation and pathology in dystrophin-deficient mice.

Authors:  Rui Xu; Neha Singhal; Yelda Serinagaoglu; Kumaran Chandrasekharan; Mandar Joshi; John A Bauer; Paulus M L Janssen; Paul T Martin
Journal:  Am J Pathol       Date:  2015-10       Impact factor: 4.307

Review 6.  Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems.

Authors:  Venkatesh P Kashi; Mark E Hatley; Rene L Galindo
Journal:  Nat Rev Cancer       Date:  2015-07       Impact factor: 60.716

7.  Induction of a regenerative microenvironment in skeletal muscle is sufficient to induce embryonal rhabdomyosarcoma in p53-deficient mice.

Authors:  Marybeth Camboni; Sue Hammond; Laura T Martin; Paul T Martin
Journal:  J Pathol       Date:  2011-10-18       Impact factor: 7.996

8.  Dystrophin and dysferlin double mutant mice: a novel model for rhabdomyosarcoma.

Authors:  Vishnu Hosur; Anoop Kavirayani; Jennifer Riefler; Lisa M B Carney; Bonnie Lyons; Bruce Gott; Gregory A Cox; Leonard D Shultz
Journal:  Cancer Genet       Date:  2012-05

9.  Muscle Stem Cells Give Rise to Rhabdomyosarcomas in a Severe Mouse Model of Duchenne Muscular Dystrophy.

Authors:  Francesca Boscolo Sesillo; David Fox; Alessandra Sacco
Journal:  Cell Rep       Date:  2019-01-15       Impact factor: 9.423

10.  Flat cells come full sphere: Are mutant cytoskeletal-related proteins oncoprotein-monsters or useful immunogens?

Authors:  Michele L Parry; George Blanck
Journal:  Hum Vaccin Immunother       Date:  2015-07-30       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.